

2018 Public Outcomes Report: Oncology Committee

The Commission on Cancer (CoC) is a group of professional organizations dedicated to improving survival and quality of life for cancer patients through standard-setting, prevention, research, education and the monitoring of comprehensive quality care.

The Oncology Committee met four times in 2018. Committee membership is defined by the CoC and required members, or their designated alternate, and are required to attend at least three of four meetings. The required members are:

- Bhanu Vakalankka, MD, medical oncologist, cancer committee chair
- Mary Cameron, MD, internal medicine, cancer liaison physician
- Maxfield Richardson, MD, general surgeon
- Margaret Ruocco, MD, pathologist
- Timothy McKone, MD and James Leenstra, MD radiation oncology
- Stephen Hite, MD, radiologist
- Amy Selly, CNP, advanced oncology certified nurse practitioner, community outreach coordinator
- Sharon Miller, BSN, RN, oncology certified nurse, clinical research coordinator
- Jean Brazil, social worker, psychosocial services coordinator
- Rhonda Mulder, quality improvement coordinator
- Shanda Phippen, MS, CGC, genetic counselor
- Erin Ferris, BSN, RN, oncology certified nurse, cancer program administrator, patient care manager, cancer conference coordinator
- Leann Osada, certified tumor registrar, cancer registry quality coordinator.

The committee also includes representation from Administration, Nutrition Services, Pharmacy, Lab, Courage Kenny Rehabilitation Institute®, Diagnostic Imaging, and the American Cancer Society (ACS).

2018 PROJECTS

The Commission on Cancer standards and eligibility requirements need to be met annually. The following outlines some of the projects completed by the Oncology Committee in 2018.

- Multidisciplinary tumor conferences are held monthly and are attended by members of the committee listed, in addition to primary care providers, infusion nurses and support staff. Tumor conferences enable the multidisciplinary team to collaborate and discuss diagnoses and optimal treatment plans for patients.
- A skin cancer screening and prevention event was held in collaboration with Tareen Dermatology, and the American Cancer Society on Wednesday, May 2, 2018. The event was based on identified community needs, and 29 community members were screened and received prevention education. The objective of the event was to increase the number of people screened for skin cancer, and to provide skin cancer prevention education. The event was made available to all community members, and was advertised in the newspaper.

Patients that had positive findings on their screening were called by cancer center staff, patients that had areas of concern were offered to schedule an appointment. The following questions were asked during the call:

(continued on next page)

Have you scheduled a follow up appointment for a biopsy?

- When is/was your appointment?
- Have you received the results?
- Are you comfortable sharing the results?
- Do you need help scheduling an appointment or information on dermatologists?

Of the patients that responded:

- One patient had questions regarding how to schedule a follow up appointment. The phone number for Dr. Tareen's office was provided.
- Two patients have a melanoma diagnosis.
- Six patients have upcoming appointments scheduled.
- One patient had a biopsy beginning of July and has a four-week follow-up scheduled to address two other areas of concern.
- Voicemails were left for 10 participants.
- Areas of concern were identified for 21 of 29 participants.

A quality study was done to determine the number of oncology patients who received oral chemotherapy education. Participants of the study were asked four questions:

Did you complete education with review of potential side effects of medication?

Do you understand the purpose of your medication?


Did anyone explain medication interaction with food or other interactions?

Do you know what to do if you miss a dose of medication?

The study results were as follows:

Virginia Piper Cancer Institute - District One Hospital Cancer Center
Chemotherapy Medication Survey Results
June 4, 2018 - July 15, 2018

% YES RESPONSES TO CHEMOTHERAPY MEDICATION SURVEY QUESTIONS



Did you complete education with review of potential side effects of medication?	32	32	0	100%
Do you understand the purpose of your medication?	32	32	0	100%
Did anyone explain medication interaction with food or other interactions?	29	15	14	52%
Do you know what to do if you miss a dose of medication?	23	14	9	61%

The following actions were taken toward quality improvement related to oral chemotherapy education and adherence.

Implement new work flow process related to oral chemotherapy management based on ONS Oral Adherence Toolkit to include, but not limiting changes to:

- oral chemotherapy education
- medication reconciliation
- food, drug and pathway interactions and effects
- medication tracking .

The clinic RN will complete the following:

- 1:1 oral chemotherapy education
 - ◇ to be scheduled and completed prior to initiation of medication.
 - ◇ informed consent completed and signed with documentation of medication, administration instructions, potential side effects and materials provided to patient
 - ◇ education will include identification and intervention of potential barriers influencing adherence
 - ◇ provide tools to increase adherence based on individual assessments:
 - medication calendar
 - pillboxes with multiple compartments (oral chemo agents may need to be kept in separate container)
 - use of electronic reminders (alarms on phones, smartphone apps)
- medication reconciliation
- follow up with nurse visit either in person or via phone monthly with prescription refills:
- oral chemotherapy patient list tracking tool to be maintained by clinic RN
- note to be entered in patient chart documenting follow up.